Zoetis (NYSE:ZTS) Stock Rating Upgraded by Zacks Research

Zoetis (NYSE:ZTS) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

ZTS has been the topic of several other research reports. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research note on Friday, August 7th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. HSBC dropped their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. UBS Group raised their price target on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a research report on Thursday, August 20th. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $98.40.

Zoetis Stock Performance

Shares of ZTS stock opened at $78.25 on Monday. The business has a 50-day moving average of $74.84 and a 200 day moving average of $94.35. Zoetis has a 1-year low of $68.77 and a 1-year high of $147.46.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same period last year, the firm earned $1.76 earnings per share. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts anticipate that Zoetis will post 6.15 EPS for the current year.

Institutional Trading of Zoetis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Physician Wealth Advisors Inc. boosted its holdings in Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after acquiring an additional 91 shares in the last quarter. Lipe & Dalton raised its holdings in Zoetis by 2.2% in the 1st quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock worth $555,000 after purchasing an additional 102 shares in the last quarter. Root Financial Partners LLC raised its holdings in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Rexford Capital Inc. lifted its position in shares of Zoetis by 5.3% in the 1st quarter. Rexford Capital Inc. now owns 2,352 shares of the company’s stock worth $278,000 after purchasing an additional 118 shares during the period. Finally, Valmark Advisers Inc. lifted its position in shares of Zoetis by 7.7% in the 1st quarter. Valmark Advisers Inc. now owns 1,747 shares of the company’s stock worth $207,000 after purchasing an additional 125 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.